These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28680903)

  • 1. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.
    Paltiel AD; Zheng A; Weinstein MC; Gaynes MR; Wood R; Freedberg KA; Sax PE; Walensky RP
    Open Forum Infect Dis; 2017; 4(2):ofx081. PubMed ID: 28680903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV cure strategies: how good must they be to improve on current antiretroviral therapy?
    Sax PE; Sypek A; Berkowitz BK; Morris BL; Losina E; Paltiel AD; Kelly KA; Seage GR; Walensky RP; Weinstein MC; Eron J; Freedberg KA
    PLoS One; 2014; 9(11):e113031. PubMed ID: 25397616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.
    Walensky RP; Park JE; Wood R; Freedberg KA; Scott CA; Bekker LG; Losina E; Mayer KH; Seage GR; Paltiel AD
    Clin Infect Dis; 2012 May; 54(10):1504-13. PubMed ID: 22474224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.
    Dugdale CM; Phillips TK; Myer L; Hyle EP; Brittain K; Freedberg KA; Cunnama L; Walensky RP; Zerbe A; Weinstein MC; Abrams EJ; Ciaranello AL;
    PLoS One; 2019; 14(11):e0225104. PubMed ID: 31730630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.
    Desmonde S; Frank SC; Coovadia A; Dahourou DL; Hou T; Abrams EJ; Amorissani-Folquet M; Walensky RP; Strehlau R; Penazzato M; Freedberg KA; Kuhn L; Leroy V; Ciaranello AL
    Open Forum Infect Dis; 2019 Jul; 6(7):ofz276. PubMed ID: 31334298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.
    Cleary SM; McIntyre D; Boulle AM
    Cost Eff Resour Alloc; 2006 Dec; 4():20. PubMed ID: 17147833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Clinical Impact and Cost-Effectiveness of Clinic-Based Cognitive Behavioral Therapy for People With HIV, Depression, and Virologic Failure in South Africa.
    Gandhi AR; Hyle EP; Scott JA; Lee JS; Shebl FM; Joska JA; Andersen LS; O'Cleirigh C; Safren SA; Freedberg KA
    J Acquir Immune Defic Syndr; 2023 Aug; 93(4):333-342. PubMed ID: 37079899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
    Meyer-Rath G; Pienaar J; Brink B; van Zyl A; Muirhead D; Grant A; Churchyard G; Watts C; Vickerman P
    PLoS Med; 2015 Sep; 12(9):e1001869. PubMed ID: 26327271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lifetime cost of current human immunodeficiency virus care in the United States.
    Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
    Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.
    Bassett IV; Govindasamy D; Erlwanger AS; Hyle EP; Kranzer K; van Schaik N; Noubary F; Paltiel AD; Wood R; Walensky RP; Losina E; Bekker LG; Freedberg KA
    PLoS One; 2014; 9(1):e85197. PubMed ID: 24465503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
    Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
    PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.